Belite Bio BLTE 深 沪
等待开盘 10-02 09:30:00 美东时间
162.98
-6.840
-4.03%
华盛通- 最 高170.36
- 今 开168.98
- 成交量 19.88万股
- 最 低 162.98
- 昨 收 169.82
- 总市值 65.64亿
- 52周最高 200.00
- 市盈率 静 --
- 换手率 0.49%
- 52周最低 78.71
- 委 比 -3.63%
- 总股本 4027.21万
- 历史最高 200.00
- 量 比 1.24
- 振 幅 4.35%
- 历史最低 8.80
- 每 手 1
- 风险率 26.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio, a clinical-stage drug development company, announced that its data will be presented at the Euretina Innovation Spotlight (EIS) on September 30, 2026, and Euretina from October 1-4, 2026, in Vienna, Austria. The EIS presentation, titled "Belite Bio Company Overview," will be delivered by Hendrik Scholl, M.D., at 2:28 – 3:06 p.m. CEST in Room 1/Hall A. The Euretina presentation, titled "Topline Results from the Phase 3 DRAGON Study of ...
09-29 00:00
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
美股周涨跌榜 | 生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周内大涨26%
生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周涨26%！受比特币反弹及云业务双重催化；Strive涨近25%，四天增持约1,800枚比特币>>
09-05 10:16
美股牛股 | Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%
Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%>>
09-05 06:25
Why Is Belite Bio Stock Soaring Friday?
Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significant upside tied to the potential launch of its lead eye-disease drug, tinlarebant. Canaccord analyst Whitney Ijem initiated coverage with a Buy rating and a $303 price forecast. That compares with Beli...
09-05 01:41
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
09-04 20:06
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio will present Phase 3 Dragon Study results for tinlarebant in Stargardt disease at the SOG Annual Congress in Lausanne, Switzerland, and the APVRS Congress in Gold Coast, Australia. Tinlarebant, an oral therapy targeting retinal diseases, aims to reduce bisretinoid accumulation caused by vitamin A-based toxins. The study met its primary endpoint and is currently in Phase 2/3 trials for STGD1 and Phase 3 trials for geographic atrophy.
08-21 12:00
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
